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Regulation of the Na1/H1 antiporter in patients with mild chronic dium-independent chloride-bicarbonate exchanger [1–6].
renal failure: Effect of glucose. An increased Na1/H1 antiporter activity has been associ-
Background. The aim of this study was to determine the ated with essential hypertension and the metabolic syn-glucose-dependent regulation of the sodium-proton-antiporter
drome [7–9]. Patients with diabetic nephropathy have(Na1/H1 antiporter) in patients with mild chronic renal fail-
ure (CRF). an elevated Na1/H1 antiporter activity compared with
Methods. We measured plasma glucose concentrations, plasma diabetic patients without diabetic nephropathy and non-
insulin concentrations, plasma C peptide concentrations, arte- diabetic control subjects [10, 11]. An increased Na1/H1rial blood pressure, cytosolic pH (pHi), cellular Na1/H1antipor-
antiporter activity has been observed in red blood cellster activity, and cytosolic sodium concentration ([Na1]i) in 19
and in lymphocytes but not in platelets from patientspatients with CRF and 41 age-matched healthy control subjects
(control) during a standardized oral glucose tolerance test. with chronic renal failure (CRF) [12, 13]. An increased
Intracellular pHi, [Na1]i, and Na1/H1 antiporter activity was Na1/H1antiporter activity has also been observed in lym-
measured in lymphocytes using fluorescent dye techniques.
phocytes from patients with end-stage renal failure onResults. Under resting conditions, the pHi was significantly
chronic hemodialysis treatment [14]. In patients with im-lower, whereas the Na1/H1 antiporter activity was significantly
higher in CRF patients compared with controls (each P , paired renal function caused by diabetes mellitus, chronic
0.0001). The oral administration of 100 g glucose significantly glomerulonephritis, or interstitial nephritis, only a propor-
increased the Na1/H1 antiporter activity in CRF patients from
tion of patients will develop end-stage renal failure.13.35 6 1.26 3 1023 pHi /second to 16.44 6 1.37 3 1023 pHi /
Among the factors that contribute to the progression ofsecond after one hour and to 14.06 6 1.36 3 1023 pHi /second
after two hours (mean 6 sem, P 5 0.008 by Friedmans’s two- CRF is poor glycemic control [15] or the predisposition
way analysis of variance). In controls, the administration of 100 to hypertension, as indicated by an increased Na1/H1
g glucose significantly increased the Na1/H1 antiporter activity antiporter activity [9, 16, 17]. Among the risk factorsfrom 4.23 6 0.20 3 1023 pHi /second to 6.00 6 0.56 3 1023
favoring the progression of renal failure, glucose haspHi /second after one hour and to 6.65 6 0.64 3 1023 pHi /
second after two hours (P 5 0.0003). The glucose-induced been shown to modulate cellular Na1/H1antiporter activ-
enhancement of the Na1/H1 antiporter activity was more pro- ity. There are several lines of evidence showing that
nounced in CRF patients compared with controls (P 5 0.011). glucose regulates the Na1/H1antiport activity. First, it hasResting [Na1]i was not significantly different between the two been shown that glucose increases the Na1/H1 antiportergroups.
activity in vascular smooth muscle cells from normoten-Conclusions. CRF patients show an intracellular acidosis
leading to an increased Na1/H1 antiporter activity. In addition, sive rats [18, 19]. Second, the incubation with 25 mmol/
high glucose levels exaggerate the differences in Na1/H1 anti- liter glucose increases the Na1/H1 antiporter activity in
porter activity already present between cells from patients with
immortalized lymphoblasts from patients with diabeticmild CRF and those from control subjects.
nephropathy [20]. Third, an increased Na1/H1 antiporter
activity has been observed in lymphocytes from healthy
subjects after the oral administration of glucose [21].Cytosolic pH (pHi) is regulated by several transport
Therefore, the specific interactions between glucose andsystems, including the sodium-proton antiporter (Na1/H1
Na1/H1 antiporter activity in patients with CRF are ofantiporter), H1-ATPases, and a sodium-dependent and so-
interest. In this study, the effects of a standardized oral
glucose challenge on blood glucose, Na1/H1 antiporterKey words: sodium-proton-antiporter, acidosis, hypertension, blood
pressure, diabetic nephropathy, end-stage renal disease. activity, and blood pressure were investigated in patients
with mild CRF and healthy control subjects (controls).Received for publication October 6, 1998
The study shows an increased Na1/H1 antiporter activityand in revised form December 21, 1998
Accepted for publication February 8, 1999 in CRF patients under resting conditions and an exagger-
ated response to an oral glucose challenge. 1999 by the International Society of Nephrology
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Table 1. Clinical and biochemical characteristics of patients with mild chronic renal failure and healthy control subjects
Healthy control Patients with mild
subjects chronic renal failure P value
Age years 4563 4563 NS
Number male/female 41 (28/13) 19 (12/7)
Body mass index kg/m2 23.560.5 27.161.1 ,0.001
Blood pressure mm Hg
Systolic 12962 15064 ,0.0001
Diastolic 7262 8763 ,0.0001
Creatinine mg/dl 0.960.0 2.060.3 ,0.001
Blood urea nitrogen mg/dl 1461 2964 ,0.001
Hemoglobin g/dl 14.060.3 13.560.4 NS
Serum potassium mmol/liter 4.460.1 4.660.1 NS
Serum sodium mmol/liter 14361 14161 NS
Values are mean 6 sem. Body mass index was calculated by body weight divided by height squared. NS denotes non-significant.
METHODS diately before (zero hr) and at one and two hours after
the oral glucose intake. The OGTT was performed ac-Patients with mild chronic renal failure and
cording to the recommendations of the National Diabe-healthy control subjects
tes Data Group [22]. The OGTT started at 8:00 a.m.Nineteen patients with mild CRF (12 males and 7
after at least three days of unrestricted diet (150 g carbo-females; mean age, 45 6 3 years; mean 6 sem) and 41
hydrate intake or more) and physical activity. The sub-healthy control subjects (28 males and 13 females; mean
jects had fasted for at least 10 hours but no more thanage, 45 6 3 years) were examined. The clinical and bio-
16 hours; water was permitted during this period. Thechemical characteristics of the CRF patients and the
OGTT took place in a quiet room with constant tempera-controls are given in Table 1. All CRF patients were
ture. A teflon cannula was inserted into an antecubitalrecruited from among outpatients. The diagnosis of CRF
vein. The subjects were in the recumbent positionwas based on serum creatinine concentrations elevated
throughout the test. After a fasting blood sample wasabove 1.1 mg/dl. CRF was due to chronic glomerulone-
collected, 100 g glucose in 400 ml flavored water (Boeh-phritis (N 5 10), interstitial nephritis (N 5 7), or polycys-
ringer, Mannheim, Germany) were drunk in approxi-tic kidney disease (N 5 2). Patients with pre-existing
mately three minutes, and blood samples were collecteddiabetes mellitus were excluded. As confirmed by the
at 60-minute intervals for two hours following the glu-clinical examination, patients were in a good state of
cose intake. Glucose concentrations were determinedhealth. No patient had significant pain, elevated temper-
using a glucose analyzer (Boehringer). Plasma insulinature, or other acute conditions. All patients were stable,
concentrations and plasma C peptide concentrationsambulatory, and free from intercurrent illness. None of
were analyzed by radioimmunoassay (Incstar Corpora-the patients were on hemodialysis. Healthy control sub-
tion, Stillwater, MN, USA). The blood pressure was mea-jects with normal kidney function were recruited in the
sured in the recumbent subject over a 10-minute periodsame manner from among outpatients with minor com-
at zero, one, and two hours after oral glucose intake withplaints (such as, skin rash, backache, etc.). Subjects with
an automatic device (DINAMAP; Critikon, Tampa, FL,a major medical illness and those who had taken pre-
USA). Ten readings of the systolic and diastolic bloodscription medications were excluded. None of the sub-
pressure were collected during the 10-minute period andjects studied had overt diabetes mellitus or gastrointesti-
were averaged.nal, hepatic, or renal disease. All participants gave their
informed consent. The study was approved by the local
Preparation of lymphocytesethical committee. Serum creatinine, blood urea nitro-
Lymphocytes were obtained according to establishedgen, hemoglobin, and serum electrolyte concentrations
techniques [23, 24]. Briefly, 20 ml of heparinized bloodwere analyzed by established laboratory methodology.
were drawn by venipuncture from the antecubital vein
Oral glucose tolerance test and were centrifuged at 240 3 g for 15 minutes. After
removing the supernatant, lymphocytes were isolated byAn oral glucose tolerance test (OGTT) was performed
layering 5 ml of diluted blood (1:1 vol:vol with isotonicin the 19 CRF patients and 41 healthy control subjects
NaCl) on 3 ml of Lymphoprep (5.6% wt/vol Ficoll; den-together with simultaneous determination of plasma glu-
sity, 1.077 g/ml; Nycomed, Uppsala, Sweden) and centrif-cose, plasma insulin, and plasma C peptide concentra-
ugation at 240 3 g for 20 minutes. The lymphocyte in-tions. Simultaneously, blood pressure, pHi, and Na1/H1
antiporter activity in lymphocytes were measured imme- terphase was carefully aspirated, washed three times in
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isotonic NaCl by centrifugation at 400 3 g for five min- The Na1/H1 antiporter was activated by the addition
of sodium propionate solution (final concentration 100utes, and resuspended in Hank’s balanced salt solution
mmol/liter) from a 1 mol/liter stock solution, pH 7.4 [13,containing (in mmol/liter): NaCl, 136; KCl, 5.4; KH2PO4,
14, 21]. The undissociated propionic acid permeated the0.44; Na2HPO4, 0.34; CaCl2, 1; D-glucose, 5.6; N-2-hy-
cell membrane and acidified the cytosol, thereby activat-droxyethylpiperazine-N9-2-ethanesulfonic acid, 10, pH
ing the Na1/H1antiporter. No changes of the fluorescence7.4. The cell preparation consisted of 22 6 1% monocytes
intensity after the addition of propionic acid occurredand 78 6 1% lymphocytes (83 6 2% T lymphocytes
at the pH-insensitive fluorescence excitation wavelengthand 17 6 6% B lymphocytes), as revealed by FACScan
of 440 nm. In control experiments, 100 mmol/liter NaCl(Becton Dickinson, Mountain View, CA, USA) using
were added that did not change the pHi. The recoveryfluorescein-isothiocyanate or phycoerythrine-labeled
of pHi was inhibited in the absence of extracellular so-monoclonal antibodies (Dianova, Hamburg, Germany).
dium, in which Na1 had been replaced by choline, indi-
cating that the recovery of pHi after intracellular acidifi-Measurements of cytosolic pH
cation is mediated by the Na1/H1 antiporter. Rate
Measurements of pHi were done according to estab- constants of the pHi recovery after intracellular acidifi-
lished methodology using a pH-sensitive fluorescent dye cation were obtained through iterative curve fitting of
[13, 14, 21, 25]. A stock solution of the pH-sensitive the experimental data to the following model: pHi,t 5
fluorescent dye 2979-bis-carboxyethyl-5(6)-carboxyfluo- pHi,x 2 (pHi,x 2 pHi,0) 3 e2kt where pHi,t is pHi at a given
time t. pHi,x is pHi at the new steady state. pHi,0 is therescein acetoxy-methylester (BCECF-AM; Sigma, Dei-
initial pHi at the moment of activation of the Na1/H1senhofen, Germany) at a final concentration of 1 mmol/
antiporter, and k is the rate constant. The rate of pHiliter was prepared in dimethylsulfoxide. The lymphocyte
recovery after intracellular acidification was computedcounts were adjusted to 106 cells/ml. The lymphocyte
using the software GraphPAD-Inplot 4.03 (GraphPadsuspension was incubated with 10 mmol/liter of cell per-
Software Inc., San Diego, CA, USA) and was expressedmeant BCECF-AM for 15 minutes at 378C. After centrif-
as pHi /second. A representative fluorescence tracing ofugation at 240 3 g for 15 minutes to remove extraneous
the pHi recovery after intracellular acidification ofdye, the lymphocyte pellet was again resuspended in
BCECF-loaded lymphocytes by propionic acid is shownHank’s balanced salt solution. Additional measurements
in Figure 2.
of resting pHi in a bicarbonate-buffered solution were
undertaken in lymphocytes, as described earlier [6]. The Measurements of cytosolic free sodium concentration
fluorescence intensity of a 1000 ml suspension of BCECF- Fluorescence measurements of [Na1]i in intact lympho-
loaded lymphocytes was measured in a thermostated cytes were performed using sodium-binding-benzofuran-
quartz cuvette with constant stirring in a fluorescence isophthalate-acetoxymethylester (SBFI-AM; Calbiochem,
spectrophotometer Model F-2000 (Hitachi Ltd., Tokyo, Bad Soden, Germany) according to published methods
Japan) using the ROM Board (251-0250; Hitachi Ltd.). [21, 27–29]. A stock solution of SBFI-AM (1 mmol/liter
The data sampling interval was 0.5 seconds, with excita- final concentration) was prepared in dimethylsulfoxide.
To 5 ml of lymphocyte suspension, 30 ml of the mem-tion wavelengths of 440 nm (representing the isosbestic,
brane-permeant SBFI-AM at a final concentration of 6pH-insensitive fluorescence excitation wavelength of
mmol/liter and 5 ml nonionic detergent Pluronic F-127BCECF) and 495 nm (representing the pH-sensitive flu-
(Molecular Probes, Eugene, USA) at a final concentra-orescence excitation wavelength of BCECF; bandwidth,
tion of 0.1% wt/vol were added. Lymphocytes were incu-10 nm), and the emission wavelength was 530 nm (band-
bated with the dye for 60 minutes at 378C. After centrifu-width, 10 nm). The autofluorescence of lymphocytes was
gation at 400 g for five minutes to remove extraneous dye,measured before the addition of the fluorescent dye and
the lymphocyte pellet was resuspended in fresh Hank’srepresented less than 1% of the fluorescence of BCECF-
balanced salt solution, pH 7.4. The fluorescence intensityloaded lymphocytes. At each lymphocyte preparation,
of 1000 ml suspension of SBFI-loaded lymphocytes (1 3
the fluorescence intensities were converted to estimates 106 cells/ml) in a thermostated quartz cuvette with con-
of pHi using the high K1/nigericin method described by stant stirring was measured in a Fluorescence Spectro-
Thomas et al [26]. Briefly, lymphocytes were resus- photometer Model F-2000 (Hitachi Ltd.) with alternate
pended in a buffer solution in which NaCl had been excitation wavelengths of 340 nm and 385 nm (bandwidth
replaced by KCl (final concentration 141.4 mmol/liter) 10 nm), and emission was collected at 500 nm (bandwidth
containing 5 mmol/liter nigericin. The calibration was 10 nm). Calibration of the F340 nm/F385 nm fluorescence
performed by sequential titrations with 0.1 mol/liter po- excitation ratio in terms of [Na1]i was performed in situ
tassium hydroxide while recording fluorescence intensity on each lymphocyte preparation. SBFI-loaded lympho-
cytes were added to solutions of known extracellular so-and extracellular pH (Fig. 1).
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Fig. 1. Calibration of fluorescence measurements
of cytosolic pH (pHi) in lymphocytes. Lympho-
cytes were loaded with the pH-sensitive fluo-
rescent dye 2979-bis-carboxyethyl-5(6)-carboxy-
fluorescein acetoxymethyl-ester (BCECF-AM)
and were suspended in a solution with known
extracellular pH containing 141.4 mmol/liter
KCl and 5 mmol/liter nigericin to equilibrate
extracellular and intracellular pH. The fluores-
cence excitation bandwidth was 10 nm, and the
fluorescence emission was collected at 530 nm.
Typical fluorescence spectra at pHi 5 6.2 and
pHi 5 7.9 are shown as insets. The ratio of the
fluorescence intensity at 495 nm and 440 nm
was calculated and plotted in terms of pH. A
calibration curve representative for 60 similar
experiments is shown.
Statistics
All data are presented as mean 6 sem. Where error
bars do not appear on figures, errors are within the sym-
bol size. Statistical analysis was performed using the
SPSS for Windows 5.01 software package (SPSS Inc.,
Chicago, IL, USA). For statistical evaluation of the data,
Friedman’s two-way analysis of variance was used, and
two-tailed P values of less than 0.05 were considered
significant. Comparisons between the two groups were
done using the Wilcoxon test, and two-tailed P values
of less than 0.05 were considered significant. The rela-
tionship between selected variables was tested by per-
Fig. 2. Plot shows a representative fluorescence tracing of 2979-bis-car- forming linear regression.
boxyethyl-5(6)-carboxyfluorescein acetoxymethyl-ester (BCECF-AM)-
loaded lymphocytes from a patient with mild chronic renal failure after
intracellular acidification with propionic acid. After the addition of 100 RESULTSmmol/liter propionic acid, the cytosolic pH (pHi) dropped immediately,
resulting in the activation of the Na1/H1 antiporter. The activity of the Effects of oral glucose challenge on plasma levels
Na1/H1 antiporter after intracellular acidification was obtained through
of glucose, insulin, and C-peptideiterative curve fitting of the experimental data to the following model:
pHi,t 5 pHi,x 2 (pHi,x 2 pHi,0) 3 e2kt where pHi,t is pHi at a given time t. After the administration of 100 g glucose, the plasma
pHi,x is pHi at the new steady state. pHi,0 is the initial pHi at the moment glucose concentration in 19 CRF patients significantlyof activation of the Na1/H1 antiporter, and k is the rate constant. The
dotted line represents the rate of pHi recovery that was obtained from raised from 96 6 5 to 187 6 10 mg/dl (1 hr after adminis-
the derivative of the curve immediately after intracellular acidification tration) and then dropped to 149 6 7 mg/dl (2 hr after
(GraphPAD-Inplot 4.03).
administration; x2 5 34.1, P , 0.0001; Fig. 3). In 41
controls, the administration of 100 g glucose significantly
increased the plasma glucose from 85 6 3 to 153 6
10 mg/dl (1 hr after administration) and then droppeddium concentration that were made by appropriate mix-
to 135 6 8 mg/dl (2 hr after administration; x2 5 49.2;tures of high-sodium and high-potassium solutions in the
P , 0.0001). It should be noted that under resting condi-presence of 5 mmol/liter monensin and 5 mmol/liter nigeri-
tions, the plasma glucose concentrations were not sig-cin. The high-sodium solution contained (in mmol/liter)
nificantly different in CRF patients compared with con-sodium gluconate 110, NaCl 30, CaCl2 1.2, MgCl2 0.6, Na-
trols (96 6 5 mg/dl, N 5 19, vs. 85 6 3 mg/dl, N 5 41,HEPES 10. The high-potassium solution was identical
except for complete replacement of sodium by potassium. P 5 0.051). On the other hand, the increase of plasma
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mg/dl, P 5 0.008; 2 hr after administration of glucose,
149 6 7 vs. 135 6 8 mg/dl, P 5 0.040).
The administration of glucose produced a significant
rise of plasma insulin concentrations in both groups
(CRF patients, x2 5 28.7, P , 0.0001; controls, x2 5 57.7,
P , 0.0001; Fig. 3). The plasma insulin concentrations
were not significantly different in CRF patients com-
pared with controls under resting conditions (13 6 3
mU/ml, N 5 19, vs. 12 6 1 mU/ml; N 5 41, P 5 0.878),
one hour after the administration of glucose (100 6 15
vs. 81 6 9 mU/ml, P 5 0.110), and two hours after the
administration of glucose (100 6 19 vs. 66 6 8 mU/ml,
P 5 0.081).
The administration of glucose produced a significant
rise of plasma C peptide concentrations in both groups
(CRF patients, x2 5 29.2, P , 0.0001; controls, x2 5 58.6,
P , 0.0001; Fig. 3). It should be noted that the plasma C
peptide concentrations were significantly higher in CRF
patients compared with controls under resting conditions
(3.78 6 0.43 ng/ml, N 5 19, vs. 1.96 6 0.28 ng/ml, N 5
41, P , 0.001), one hour after administration of glucose
(11.15 6 1.20 vs. 7.10 6 0.85 ng/ml, P , 0.01), and two
hours after the administration of glucose (12.47 6 1.50
vs. 6.84 6 0.91 ng/ml, P , 0.001).
Effects of oral glucose challenge on heart rate
and blood pressure
During an oral glucose challenge, the heart rate was
not significantly changed in 19 CRF patients, whereas a
significant increase of heart rate could be observed in
41 controls (CRF patients: zero hr, 75 6 3/min; 1 hr,
75 6 3/min; 2 hr, 71 6 3/min, x2 5 4.1, P 5 0.127; controls:
zero hr, 75 6 2/min; 1 hr, 79 6 2/min; 2 hr, 78 6 2/
min, x2 5 10.8, P 5 0.004). Systolic and diastolic blood
pressures were significantly higher in CRF patients com-
pared with controls (P , 0.0001). During an oral glucose
challenge, the systolic and diastolic blood pressure sig-
nificantly decreased in the CRF patients (systolic/dia-
stolic blood pressure, zero hr, 150 6 4/87 6 3 mm Hg;
1 hr, 140 6 3/81 6 3 mm Hg; 2 hr, 142 6 4/83 6 3 mm
Fig. 3. Effect of oral glucose challenge on (A) plasma glucose, (B) Hg; x2 5 19.9/7.7; P , 0.0001/P 5 0.021), whereas in
plasma insulin, and (C) plasma C peptide concentrations. The plasma
controls, the systolic and the diastolic blood pressure didconcentrations of glucose, insulin, and C peptide were evaluated in
patients with mild chronic (N 5 19; j) and healthy control subjects not change significantly (systolic/diastolic blood pres-
(N 5 41; h) after an overnight fast (zero hr) and one and two hours sure, zero hr, 129 6 2/72 6 2 mm Hg; 1 hr, 128 6 2/70 6
after the administration of 100 g glucose [oral glucose tolerance test
2 mm Hg; 2 hr, 127 6 2/70 6 2 mm Hg; x2 5 0.2/1.6,(OGTT)]. Values represent the mean 6 sem. Where error bars do not
appear, errors are within the symbol size. After the administration of P 5 0.891/P 5 0.444).
glucose, the plasma glucose concentrations (***P , 0.0001), plasma
insulin concentrations (***P , 0.0001), and plasma C peptide concen- Effects of oral glucose challenge on pHi and Na1/H1trations (***P , 0.0001) increased significantly, as determined by Fried-
antiporter activityman’s two-way analysis of variance.
As shown in Figure 4, the cytosolic pHi was signifi-
cantly lower in lymphocytes from CRF patients com-
pared with controls under resting conditions (7.03 6
glucose after an oral glucose challenge was significantly 0.03, N 5 19, vs. 7.36 6 0.03, N 5 41; P , 0.0001), one
higher in CRF patients compared with controls (1 hr hour after administration of glucose (7.06 6 0.03 vs.
7.33 6 0.03, P , 0.0001), and two hours after the adminis-after administration of glucose, 187 6 10 vs. 153 6 10
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Fig. 4. Scatterplot shows resting cytosolic pH (resting pHi) in lympho- Fig. 5. Scatterplot shows the buffering capacity in lymphocytes loaded
cytes loaded with the pH-sensitive fluorescent dye 2979-bis-carboxyethyl- with the pH-sensitive fluorescent dye 2979-bis-carboxyethyl-5(6)-car-
5(6)-carboxyfluorescein acetoxymethyl-ester (BCECF-AM). The effect boxyfluorescein acetoxymethyl-ester (BCECF-AM). The effect of an
of an oral glucose challenge on the resting pHi in patients with mild oral glucose challenge on the buffering capacity in patients with mild
chronic renal failure (N 5 19; j) and healthy control subjects (N 5 chronic renal failure (N 5 19; j) and healthy control subjects (N 5
41; h) is shown. Measurements were undertaken after an overnight 41; h) is shown. Measurements were undertaken after an overnight
fast (zero hr) and one and two hours after the administration of 100 g fast (zero hr) and one and two hours after the administration of 100 g
glucose [oral glucose tolerance test (OGTT)]. Mean values are indicated glucose [oral glucose tolerance test (OGTT)]. The mean values are
beside the scattered data. Resting pHi was significantly lower in patients indicated beside the scattered data. The buffering capacity was signifi-
with mild chronic renal failure compared with healthy control subjects cantly lower in patients with mild chronic renal failure compared with
(***P , 0.0001). healthy control subjects (***P , 0.0001).
tration of glucose (7.03 6 0.02 vs. 7.31 6 0.03, P ,
0.0001). During an oral glucose challenge, there was no
significant change of pHi in either lymphocytes from
CRF patients (x2 5 2.2, P 5 0.331) or in lymphocytes
from controls (x2 5 3.0, P 5 0.222). Separate measure-
ments of resting pHi in a bicarbonate-buffered solution
were undertaken in lymphocytes from CRF patients and
controls. Under these conditions, the resting pHi was not
significantly different in lymphocytes from CRF patients
(7.23 6 0.03, N 5 19) and healthy control subjects (7.28 6
0.02, N 5 25, P 5 0.162).
As indicated in the literature [13], the changes in the
pHi after the addition of similar amounts of propionic
acid are a reflection of the cytosolic buffering capacity for
H1. The intracellular buffering capacity in lymphocytes
from CRF patients and from controls is shown in Figure
5. The intracellular buffering capacity was significantly
Fig. 6. Effect of oral glucose challenge on the Na1/H1antiporter activitylower in lymphocytes from CRF patients compared with
in patients with mild chronic renal failure (N 5 19; j) and healthycontrols under resting conditions (0.44 6 0.03, N 5 19,
control subjects (N 5 41; h). Measurements were undertaken after an
vs. 0.75 6 0.02, N 5 41, P , 0.0001), one hour after the overnight fast (zero hr) and one and two hours after the administration
of 100 g glucose [oral glucose tolerance test (OGTT)]. The recoveryadministration of glucose (0.48 6 0.03 vs. 0.72 6 0.03,
rate of cytosolic pHi in lymphocytes loaded with the pH-sensitive fluo-P , 0.0001), and two hours after the administration of rescent dye BCECF-AM was evaluated after intracellular acidification
glucose (0.42 6 0.03 vs. 0.71 6 0.03, P , 0.0001). with 100 mmol/liter propionic acid. The initial rates of pHi recovery
immediately after intracellular acidification were determined and repre-The Na1/H1 antiporter activity was measured after in-
sent the Na1/H1 antiporter activity. The Na1/H1 antiporter activity wastracellular acidification. As shown in Figure 6, the Na1/H1 significantly higher in patients with mild chronic renal failure compared
antiporter activity was significantly higher in CRF pa- with healthy control subjects at zero, one, and two hours after the
administration of glucose (each ***P , 0.0001). During the OGTT,tients compared with controls under resting conditions
there was a significant increase of the Na1/H1 antiporter activity in(13.35 6 1.26 3 1023 pHi /second, N 5 19, vs. 4.23 6 lymphocytes from patients with mild chronic renal failure (P , 0.0001)
and from healthy control subjects (P 5 0.0080).0.20 3 1023 pHi /second, N 5 41, P , 0.0001), one hour
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Table 2. Effect of oral glucose challenge on lymphocytic
pH (pHi) in patients with mild chronic renal failure and
healthy control subjects
Pataients with mild
Healthy control subjects chronic renal failure
Time pHi,r pHi,0 pHi,r pHi,0
Zero hour 7.3660.03 6.62 60.03 7.03 60.03 6.58 60.03
One hour 7.3360.03 6.63 60.03 7.06 60.03 6.58 60.03
Two hours 7.3160.03 6.61 60.03 7.03 60.02 6.64 60.02
Resting pHi (pHi,r) was measured in intact lymphocytes using the pH-sensitive
fluorescent dye, 2979-bis-carboxyethyl-5(6)-carboxyfluorescein (BCECF). The
Na1/H1 antiporter was measured after intracellular acidification of lymphocytes
by 100 mmol/liter propionic acid. Three consecutive measurements were done
after an overnight fast (0 hr), and 1 hr, and 2 hr after the administration of 100
g glucose (oral glucose tolerance test, OGTT). Values are mean 6 sem from 19
CRF patients and 41 controls. pHi,0 indicates pHi values after addition of propi-
onic acid immediately before pHi recovery. pHi,0 was not significantly different
during OGTT in CRF patients (x2 5 5.1; P 5 0.080) or in controls (x2 5 1.5;
P 5 0.478).
Fig. 7. Effect of oral glucose challenge on the cytosolic free sodium
concentration ([Na1]i) in patients with mild chronic renal failure (j)
and healthy control subjects (h). Measurements were undertaken after
an overnight fast (zero hr) and one and two hours after the administra-
after the administration of glucose (16.44 6 1.37 3 1023 tion of 100 g glucose [oral glucose tolerance test (OGTT)]. Resting
[Na1]i was measured spectrophotometrically in lymphocytes loaded withpHi /second vs. 6.00 6 0.56 3 1023 pHi /second, P ,
the sodium-sensitive fluorescent dye SBFI-AM.0.0001), and two hours after the administration of glu-
cose (14.06 6 1.36 3 1023 pHi /second vs. 6.65 6 0.64 3
1023 pHi /second, P , 0.0001). The oral administration
of 100 g glucose significantly increased the Na1/H1 anti- 2 mmol/liter; x2 5 3.2, P 5 0.1969; control: zero hr, 5 6
porter activity in CRF patients from 13.35 6 1.26 3 1023 1 mmol/liter; 1 hr, 7 6 1 mmol/liter; 2 hours, 7 6 1 mmol/
pHi /second to 16.44 6 1.37 3 1023 pHi /second after one liter; x2 5 1.8, P 5 0.4066; Fig. 7). Under resting condi-
hour and to 14.06 6 1.36 3 1023 pHi/second after two tions, the [Na1]i concentrations were not significantly
hours (x2 5 9.8, P 5 0.0080). In controls, the administra- different in CRF patients compared with controls.
tion of 100 g glucose significantly increased the Na1/H1
antiporter activity from 4.23 6 0.20 3 1023 pHi /second In vitro effects of glucose on the Na1/H1
antiporter activityto 6.00 6 0.56 3 1023 pHi /second after one hour and to
6.65 6 0.64 3 1023 pHi /second after two hours (x2 5 For further evaluation of the underlying mechanisms,
16.1, P 5 0.0003). It should be noted that the absolute in vitro studies using glucose and agonists and antago-
glucose-induced enhancement of the Na1/H1 antiporter nists of the protein kinase C were tested in vitro. The
activity was more pronounced in CRF patients compared exposure of lymphocytes from healthy control subjects
with controls (3.09 6 0.97 3 1023 pHi /second vs. 1.78 6 to 500 mg/dL glucose for one hour in vitro did not signifi-
0.52 3 1023 pHi /second, P 5 0.011). However, the per- cantly change the activity of the Na1/H1 antiporter (68 6
centage increase over resting activity of the Na1/H1 anti- 2% of the control value, P 5 0.079). On the other hand,
porter was not significantly different between CRF pa- the exposure of lymphocytes from healthy control sub-
tients compared with controls (30 6 9 vs. 44 6 12%, jects to 10 nmol/liter phorbol Myristate acetate for one
P 5 0.949). Importantly, the pHi immediately after intra- hour in vitro significantly enhanced the activity of the
cellular acidification (pHi,0) was not significantly different Na1/H1 antiporter (183 6 29% of the control value, P 5
between the groups or within the two groups during the 0.001), whereas the addition of 10 nmol/liter bisindolyl-
oral glucose challenge (Table 2). maleimide showed no significant effect (129 6 43% of
In the 19 CRF patients, no significant correlation be- the control value, P 5 0.135).
tween the Na1/H1 antiporter activity and systolic or dia-
stolic blood pressure, plasma glucose concentration,
DISCUSSIONplasma insulin concentration, or plasma C peptide con-
centration could be observed (each P . 0.05). The interactions between glucose metabolism and cel-
lular ion transport systems such as Na1/H1 antiporter
Effects of oral glucose challenge on cytosolic free have been examined in studies either in vitro or in
sodium concentration healthy subjects. However, these interactions have not
yet been studied in detail under the conditions of renalDuring an oral glucose challenge, [Na1]i did not sig-
nificantly change in CRF patients or in controls (CRF: failure. Nevertheless, in patients with CRF, an impaired
glucose metabolism is an important factor that acceler-zero hr, 6 6 1 mmol/liter; 1 hr, 6 6 2 mol/liter; 2 hr, 7 6
Tepel et al: Glucose, Na1/H1 antiporter and CRF 179
ates the progress of renal failure, and therefore, the im- kinase C has been reported [19, 33, 34]. This study indi-
pact of glucose metabolism and renal failure on Na1/H1 cates that the administration of glucose in vitro did not
antiporter activity may be of potential clinical relevance. significantly change the activity of the Na1/H1 antiporter.
These data suggest that insulin resistance appears in pa- On the other hand, phorbol Myristate acetate, an activa-
tients with CRF because the increase of plasma glucose tor of protein kinase C, in vitro significantly enhanced
during an oral glucose challenge was significantly higher the activity of the Na1/H1 antiporter in lymphocytes.
in patients with CRF compared with healthy control These results are similar to the findings that long-term
subjects. In addition, elevated plasma C peptide levels exposure of vascular smooth muscle cells to a high-glu-
were seen in CRF patients. However, resting and stimu- cose medium stimulated the activity of the Na1/H1 anti-
lated insulin levels were not significantly different be- porter by a protein kinase C-dependent mechanism [19].
tween the two groups under resting conditions or one The possibility that insulin stimulates the activity of the
or two hours after an oral glucose challenge. Na1/H1 antiporter in lymphocytes has already been ex-
The study revealed that both renal failure and glucose cluded in an earlier study using the euglycemic hyperin-
metabolism interact in modulating Na1/H1 antiporter. sulinemic clamp technique in vivo [21].
Patients with CRF showed an increased Na1/H1 antipor- Another important finding is that the increased Na1/H1
ter activity, which is in accord with earlier findings [11– antiporter activity in patients with CRF is not sufficient
14]. Furthermore, there was a decreased resting pHi, to correct the intracellular acidosis. Currently, it can
which may be one cause of the increased Na1/H1antipor- only be speculated about the causes of the insufficient
ter activity. Besides the elevated Na1/H1antiporter activ- response of the Na1/H1 antiporter. Recent studies indi-
ity in the fasting state, there was an exaggerated response cate that in CRF, not only the Na1/H1 antiporter but also
of the absolute Na1/H1 antiporter activity to stimulation the Cl2/HCO32exchanger is an important determinant ofby oral glucose administration. cytosolic pHi [6, 35]. Concomitant changes in the Cl2/In this study, the activity of the Na1/H1 antiporter was HCO32 exchanger may impair the adequate compensa-measured after intracellular acidification using sodium tion of pHi by the Na1/H1 antiporter. Recently, the activ-propionate. The addition of sodium propionate for intra-
ity of the sodium-dependent and sodium-independent
cellular acidification for the determination of the activity
Cl2/HCO32 exchanger has been reported in lymphocytesof the Na1/H1 antiporter is an established technique that
from CRF patients and healthy control subjects [6].offers several advantages [13]. The experimental han-
There was a significant negative correlation of the so-dling of the lymphocytes is minimized and additional
dium-dependent Cl2/HCO32 exchanger with increasingcentrifugation steps that might damage the cells are
creatinine concentrations. Because the activation of theavoided. On the other hand there are some limitations
sodium-dependent Cl2/HCO32 exchanger produces in-of that method, the dampening of the rate of Na1/H1
tracellular alkalization by extrusion of chloride and intra-antiporter activity by continuous influx of propionic acid
cellular accumulation of HCO32. Therefore, it appearsthat continues to acidify the cytosol. However, these
that the elevated Na1/H1 antiporter activity is counter-limitations should appear in lymphocytes from patients
balanced by an impaired Cl2/HCO32 exchanger activitywith CRF and healthy control subjects to an equivalent
in patients with CRF [6]. A further explanation couldextent and should not affect the main findings of this
be that in uremia, mainly organic acids generated bystudy. In addition, it should be noted that the pHi after
protein breakdown contribute to the intracellular andthe addition of propionic acid immediately before the
extracellular acidosis. Because of the relative high mem-pHi recovery (pHi,0) was not significantly different during
brane permeability of these organic acids, the Na1/H1the OGTT in CRF patients or in controls. Therefore,
antiporter may easily be shunted, thus preventing anthe differences of the Na1/H1 antiporter activity in lym-
adequate control of intracellular acidosis.phocytes from CRF patients and from controls are not
Taken together, this study shows that glucose has en-due to different initial starting pHi,0.
hanced effects on the Na1/H1 antiporter activity in pa-How can the enhanced response of the Na1/H1antipor-
tients with CRF. Given a role of Na1/H1 antiporter activ-ter to glucose be explained? The chronic intracellular
acidosis in patients with CRF may lead to an increased ity in the regulation of cellular growth, this effect of
expression of Na1/H1 antiporter and hence to an en- glucose may be part of the mechanisms underlying the
hanced response to physiological stimuli [10, 30–32]. role of glucose as a factor enhancing the progression of
Moreover, renal failure with accumulation of uremic tox- CRF. One cause of the enhanced Na1/H1 antiporter may
ins may affect the signal transduction pathways by which be the profound cytosolic acidosis.
the effect of glucose on Na1/H1 antiporter activity is
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